Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis
Authors:
Open Access
Abstract
Background and aims: Ulcerative colitis disease activity indices offer good statistical power but small changes in these indices may not be clinically important. There are no validated definitions of remission or of significant improvement for these indices. The use of clinically important end points would strengthen the validity of study outcomes. Our aims were to identify objective end points in standard disease activity indices for remission and for improvement in ulcerative colitis. Methods: Sixty six consecutive patients with ulcerative colitis provided information about remission status and their disease activity. At a return visit 1–14 months later, these patients provided information about the change in their disease activity, and non-invasive indices were measured. Results: Specific objective end points for determining remission with four standard indices and a quality of life instrument were determined (St Mark’s 1.5, Seo decrease >30, IBDQ increase >20). Conclusions: We found specific cut off values for disease activity indices that identify patients who have significantly improved or achieved remission in an objective, sensitive, and specific manner. These cut offs should help in the interpretation of the outcomes of clinical trials in ulcerative colitis.Keywords
This publication has 16 references indexed in Scilit:
- Is Endoscopy Necessary for the Measurement of Disease Activity in Ulcerative Colitis?American Journal of Gastroenterology, 2005
- Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial management, data analysis, and writing the paper. Maja Noman had a major contribution in the clinical ambulatory follow-up of the patients in the trial. Martin Hiele followed cyclosporine levels and adjusted drug doses of patients in the trial and provided statistical advice. Katrien Asnong was the study coordinator and had a major share in data analysis. Joris Arts analyzed safety data and followed patients clinically during the trial. Andre D’Hoore and Freddy Penninckx performed the surgical interventions in patients failing the trial and substantially contributed in evaluating patients for colectomy.Gastroenterology, 2003
- Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel diseaseAmerican Journal of Gastroenterology, 2003
- Epidermal Growth Factor Enemas with Oral Mesalamine for Mild-to-Moderate Left-Sided Ulcerative Colitis or ProctitisNew England Journal of Medicine, 2003
- Complementary and Alternative Medicine Use by Canadian Patients With Inflammatory Bowel Disease: Results From A National SurveyAmerican Journal of Gastroenterology, 2003
- Utilization of Complementary and Alternative Medicine by United States AdultsMedical Care, 2002
- An index of disease activity in patients with ulcerative colitis.1992
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitisGastroenterology, 1987
- A Comparison of Oral Prednisolone Given as Single or Multiple Daily Doses for Active ProctocolitisScandinavian Journal of Gastroenterology, 1978